Ubs Asset Management Americas Inc Janux Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 186,394 shares of JANX stock, worth $4.44 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
186,394
Previous 165,737
12.46%
Holding current value
$4.44 Million
Previous $8.87 Million
43.29%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding JANX
# of Institutions
193Shares Held
57.3MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$266 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$109 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$87 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$79.3 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$55.8 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $992M
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...